Medical treatment of pruritus

Expert Opinion on Emerging Drugs

Volumn 17, Issue 3, 2012, Pages 335-345

  Ständer, Sonja ^a   Weisshaar, Elke ^b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Atopic dermatitis; Itch; Prurigo; Pruritus; Substance P

Indexed keywords

1 (5 CHLORO 2 INDOLYLCARBONYL) 4 METHYLPIPERAZINE; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; APREPITANT; CALCITONIN GENE RELATED PEPTIDE; CYCLOSPORIN; FILAGGRIN; GABAPENTIN; GASTRIN RELEASING PEPTIDE RECEPTOR; GRANISETRON; HISTAMINE H4 RECEPTOR; INTERLEUKIN 31; KAPPA OPIATE RECEPTOR; MIRTAZAPINE; NALFURAFINE; NALTREXONE; NERVE GROWTH FACTOR; NEUROTROPHIN 4; ONDANSETRON; OPIATE ANTAGONIST; PAROXETINE; PREGABALIN; PROSTAGLANDIN D2; PROTEINASE ACTIVATED RECEPTOR 2; SUBSTANCE P; TACHYKININ RECEPTOR; TACHYKININ RECEPTOR ANTAGONIST; UNINDEXED DRUG; VANILLOID RECEPTOR 1;

CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG EFFICACY; HEADACHE; HUMAN; INSOMNIA; NAUSEA; NEUROBIOLOGY; NONHUMAN; NORWAY; PHOTOTHERAPY; PROTEIN EXPRESSION; PRURITUS; REVIEW; SOMNOLENCE; SYNAPTIC TRANSMISSION; TH2 CELL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VERTIGO; VISUAL ANALOG SCALE; VOMITING;

ANTIPRURITICS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; PRURITUS; QUALITY OF LIFE; RECEPTORS, NEUROKININ-1; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84865610583     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2012.711316     Document Type: Review

References (90)

1. Weisshaar E, Szepietowski JC, Darsow U, et al. European Guideline for Chronic Pruritus. 2010. Available from: http://www.euroderm.org/images/stories/ guidelines/EDF-Guideline-on-Chronic-Pruritus.pdf Acta DermatoVeneraol 2012, in press
2. Metz M, Ständer S. Chronic pruritus-pathogenesis, clinical aspects and treatment. J Eur Acad Dermatol Venereol 2010;24:1249-60
3. Ständer S, Raap U. Weisshaar E, et al. [Pathogenesis of Pruritus]. J Dtsch Dermatol Ges 2011;9:456-63
4. Raap U, Ständer S, Metz M. Pathophysiology of itch and new treatments. Curr Opin Allergy Clin Immunol 2011;11:420-7
5. Dalgard F, Svensson A, Holm JO, et al. Self-reported skin morbidity in Oslo. Associations with socio-demographic factors among adults in a cross-sectional study. Br J Dermatol 2004;151:452-7 (Pubitemid 39220333)
6. Ständer S, Schäfer I, Phan NQ, et al. Prevalence of chronic pruritus in Germany: results of a cross-sectional study in a sample working population of 11,730. Dermatology 2010;221:229-35
7. Matterne U, Apfelbacher CJ, Loerbroks A, et al. Prevalence, correlates and characteristics of chronic pruritus. A population-based cross-sectional study. Acta Derm Venereol 2011;91:674-9
8. Vogelgsang L, Loerbroeks A, Apfelbacher CJ, et al. Incidence of chronic pruritus and its determinants: results from a population-based study. Exp Dermatol 2012;21:e1-e48
9. Ständer S, Luger T. Itch in atopic dermatitis-pathophysiology and treatment. Acta Dermatovenerol Croat 2010;18:289-96
10. Weisshaar E, Dalgard F. Epidemiology of itch. Adding to the burden of skin morbidity. Acta Derm Venereol 2009;89:339-50
11. Weisshaar E. Pruritus and psoriasis: an often, but frequently underestimated relation. Hautarzt 2012;63:547-52
12. Dawn A, Papoiu AD, Chan YH, et al. Itch characteristics in atopic dermatitis: results of a web-based questionnaire. Br J Dermatol 2009;160:642-4
13. Weisshaar E, Apfelbacher CJ, Jäger G, et al. Pruritus as a leading symptom: clinical characteristics and quality of life in German and Ugandan patients. Br J Dermatol 2006;155:957-64 (Pubitemid 44566368)
14. Sommer F, Hensen P, Bockenholt B, et al. Underlying diseases and co-factors in patients with severe chronic pruritus: a 3-year retrospective study. Acta Derm Venereol 2007;78:510-16 (Pubitemid 351373395)
15. Ständer S, Weisshaar E, Mettang T, et al. Clinical classification of itch: a position paper of the International Forum for the Study of Itch. Acta Derm Venereol 2007;87:291-4
16. Ständer S, Streit M, Darsow U, et al. Guideline: diagnostic and therapeutic procedures in chronic pruritus. J Dtsch Dermatol Ges 2006;4:350-70 (Pubitemid 44143802)
17. Siepmann D, Weishaupt C, Luger TA, et al. Evaluation of the German guideline for chronic pruritus: results of a retrospective study on 385 patients. Dermatology 2011;223:374-80
18. Schmelz M, Schmidt R, Bickel A, et al. Specific C-receptors for itch in human skin. J Neurosci 1997;17:8003-8 (Pubitemid 27426235)
19. Ständer S, Schmelz M. Chronic itch and pain-similarities and differences. Eur J Pain 2006;10:473-8
20. Namer B, Carr R, Johanek LM, et al. Separate peripheral pathways for pruritus in man. J Neurophysiol 2008;100:2062-9
21. Johanek LM, Meyer RA, Hartke T, et al. Psychophysical and physiological evidence for parallel afferent pathways mediating the sensation of itch. J Neurosci 2007;27:7490-7 (Pubitemid 47066576)
22. Darsow U, Pfab F, Valet M, et al. Pruritus and atopic dermatitis. Clin Rev Allergy Immunol 2011;4:237-44
23. Abadia Molina F, Burrows NP, Jones RR, et al. Increased sensory neuropeptides in nodular prurigo: a quantitative immunohistochemical analysis. Br J Dermatol 1992;127:344-51
24. Jarvikallio A, Harvima IT, Naukkarinen A. Mast cells, nerves and neuropeptides in atopic dermatitis and nummular eczema. Arch Dermatol Res 2003;295:2-7 (Pubitemid 36578014)
25. Papoiu AD, Wang H, Nattkemper L, et al. A study of serum concentrations and dermal levels of NGF in atopic dermatitis and healthy subjects. Neuropeptides 2011;45:417-22
26. Tominaga M, Tengara S, Kamo A, et al. Psoralen-ultraviolet A therapy alters epidermal Sema3A and NGF levels and modulates epidermal innervation in atopic dermatitis. J Dermatol Sci 2009;55:40-6
27. Grewe M, Vogelsang K, Ruzicka T, et al. Neurotrophin-4 production by human epidermal keratinocytes: increased expression in atopic dermatitis. J Invest Dermatol 2000;114:1108-12 (Pubitemid 30415225)
28. Denda M, Sokabe T, Fukumi-Tominaga T, et al. Effects of skin surface temperature on epidermal permeability barrier homeostasis. J Invest Dermatol 2007;127:654-9
29. Takaoka A, Arai I, Sugimoto M, et al. Expression of IL-31 gene transcripts in NC/Nga mice with atopic dermatitis. Eur J Pharmacol 2005;516:180-1 (Pubitemid 40799355)
30. Sonkoly E, Muller A, Lauerma AI, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006;117:411-17 (Pubitemid 43192023)
31. Cornelissen C, Marquardt Y, Czaja K, et al. IL-31 regulates differentiation and filaggrin expression in human organotypic skin models. J Allergy Clin Immunol 2012;129:426-33.e1-8
32. Nobbe S, Dziunycz P, Mühleisen B, et al. IL-31 expression by inflammatory cells is preferentially elevated in atopic dermatitis. Acta Derm Venereol 2012;92:24-8
33. Gutzmer R, Mommert S, Gschwandtner M, et al. The histamine H4 receptor is functionally expressed on T(H)2 cells. J Allergy Clin Immunol 2009;123:619-25
34. Andrew D, Craig AD. Spinothalamic lamina 1 neurons selectively sensitive to histamine: a central neural pathway for itch. Nat Neurosci 2001;4:72-7 (Pubitemid 32095528)
35. Sun YG, Chen ZF. A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature 2007;448:700-3
36. Sun YG, Zhao ZQ, Meng XL, et al. Cellular basis of itch sensation. Science 2009;325:1531-4
37. Weisshaar E, Ständer S, Gieler U, et al. Development of a German language questionnaire for assessing chronic pruritus (AGP-questionnaire): background and first results. Hautarzt 2011;62:914-27
38. Schneider G, Driesch G, Heuft G, et al. Psychosomatic cofactors and psychiatric comorbidity in patients with chronic itch. Clin Exp Dermatol 2006;31:762-7 (Pubitemid 44563391)
39. O' Donoghue M, Tharp MD. Antihistamines and their role as antipruritics. Dermatol Ther 2005;18:333-40 (Pubitemid 41801853)
40. Zuberbier T, Bindslev-Jensen C, Canonica W, et al. EAACI/Galen Guideline: management of urticaria. Allergy 2005;61:321-31
41. Schulz S, Metz M, Siepmann D, et al. Antipruritic efficiency of a high-dosage antihistaminic therapy. Results of a retrospectively analyzed case series. Hautarzt 2009;60:564-8
42. Apfelbacher CJ, Ebert I, Scheidt R, et al. H1 antihistamines for eczema. A systematic review. Cochrane Skin Group Protocols. 2009. Available from: http://summaries.cochrane.org/CD007770/h1-antihistamines-for-eczema
43. Kawashima M, Tango T, Nogushi T, et al. Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multi-center, double-blind, placebo-controlled, parallel-group study. Br J Dermatol 2003;148:1212-21 (Pubitemid 36819222)
44. Murota H, Kitaba S, Tani M, et al. Impact of sedative and non-sedative antihistamines on the impaired productivity and quality of life in patients with pruritus skin diseases. Allergol Int 2010;59:345-54
45. Argoff CE, Katz N, Backonja M. Treatment of postherpetic neuralgia: a review of therapeutic options. J Pain Symptom Manage 2004;28:396-11 (Pubitemid 39313169)
46. Misery L. Gabapentin in dermatology. Dermatology 2005;211:79-80 (Pubitemid 41160238)
47. Kanitakis J. Brachioradial pruritus. report of a new case responding to gabapentin. Eur J Dermatol 2006;16:311-12 (Pubitemid 43736159)
48. Yesudian PD, Wilson NJE. Efficiency of gabapentin in the management of pruritus of unknown origin. Arch Dermatol 2005;141:1507-9 (Pubitemid 41819025)
49. Gunal AI, Ozalp G, Yoldas TK, et al. Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant 2004;19:3137-9 (Pubitemid 40063517)
50. Ehrchen J, Ständer S. Pregabalin in the treatment of chronic pruritus. J Am Acad Dermatol 2008;58(2 Suppl):S36 7
51. Porzio G, Aielli F, et al. Efficiency of pregabalin in the management of cetoximab-related itch. J Pain Symptom Manage 2006;32:397-8 (Pubitemid 44666299)
52. Phan NQ, Bernhard JD, Luger TA, et al. Antipruritic treatment with systemic μ-opioid receptor antagonists: a review. J Am Acad Dermatol 2010;19:58-65
53. Phan NQ, Lotts T, Antal A, et al. Systemic kappa opioid receptor (KOR) agonists in the treatment of chronic pruritus: a review. Acta DermatoVenereol 2012; In press
54. Wikstrom B, Gellert R, Ladefoged SD, et al. Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol 2005;16:3742-7 (Pubitemid 46211297)
55. Kumagai H, Ebata T, Takamori K, et al. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant 2010;25:1251-7
56. Davis MP, Frandsen JL, Walsh D, et al. Mirtazapine for pruritus. J Pain Symptom Manage 2003;25:288-91 (Pubitemid 36287087)
57. Tefferi A, Von Fonseca R. Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. Blood 2002;99:27
58. Zylicz Z, Smits C, Krajnik M. Paroxetine for pruritus in advanced cancer. J Pain Symptom Manage 1998;16:121-4 (Pubitemid 28400162)
59. Biondi M, Arcangeli T. Paroxetine in a case of psychogenic pruritus and neurotic excoriations. Psychother Psychosom 2000;69:165-6 (Pubitemid 30223588)
60. Zylicz Z, Krajnik M. Paroxetine in the treatment of severe non-dermatological pruritus: a randomized, controlled trial. J Pain Symptom Manage 2003;26:1105-12 (Pubitemid 37488018)
61. Ständer S, Bockenholt B, Schürmeyer-Horst F, et al. Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-armed, prove-off-concept study. Acta Derm Venereol 2009;89:45-51
62. Schworer H, Hartmann H, Ramadori G, et al. Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron. Pain 1995;61:33-7
63. Raderer M, Muller C, Scheithauer W, et al. Ondansetron for pruritus due to cholestasis. N Engl J Med 1994;330:40
64. Andrews PA, Quan V, Ogg CS. Ondansetron for symptomatic relief in terminal uraemia. Nephrol Dial Transplant 1995;10:140
65. Albares M P, Betlloch I, Guijarro J, et al. Severe pruritus in a haemodialysed patient: dramatic improvement with granisetron. Br J Dermatol 2003;148:376-7 (Pubitemid 36278996)
66. O' Donohue JW, Haigh C, et al. Ondansetron in the treatment of cholestasis: a randomised controlled trial. Gastroenterology 1997;112:A1349
67. Muller C, Pongratz S, Pidlich J, et al. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol 1998;10:865 70
68. Larijani GE, Goldberg ME, et al. Treatment of opioid-induced pruritus with ondansetron: report of four patients. Pharmacotherapy 1996;16:958-60 (Pubitemid 26322200)
69. Kjellberg F, Tramer MR. Pharmacological control of opioid-induced pruritus: a quantitative systematic review of randomized trials. Eur J Anaesthesiol 2001;18:346-57 (Pubitemid 34603784)
70. Ashmore SD, Jones CH, Newstead CG, et al. Ondansetron therapy for uremic pruritus in hemodialysis patients. Am J Kidney Dis 2000;35:827-31 (Pubitemid 30238193)
71. Murphy M, Reaich D, Pai P, et al. A randomized, placebo-controlled, double-blind trial of ondansetron in renal itch. Br J Dermatol 2003;148:314-17 (Pubitemid 36278974)
72. Weisshaar E, Dunker N, Rohl FW, et al. Antipruritic effects of two different 5-HT3 receptor antagonists and an antihistamine in haemodialysis patients. Exp Dermatol 2004;13:298-04 (Pubitemid 38714429)
73. Berth-Jones J, Smith SG, Graham-Brown RA. Nodular prurigo responds to cyclosporin. Br J Dermatol 1995;132:795-9
74. Siepmann D, Luger TA, Ständer S, et al. Antipruritic effect of cyclosporine microemulsion in prurigo nodularis: results of a case series. J Dtsch Dermatol Ges 2008;6:941-6
75. Staab D, Diepgen TL, Fartasch M, et al. Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multi-center, randomised controlled trial. BMJ 2006;332:933-8
76. Evers A, P, Duller P, et al. Effectiveness of a multidisciplinary itch-coping training programme in adults with atopic dermatitis. Acta Derm Venereol 2009;89:57-63
77. Van Oos-Medendorp H, Ros WJG, Eland-de Kok CM, et al. Effectiveness of the nursing programme "Coping with itch": a randomized controlled study in adults with chronic pruritic skin disease. Br J Dermatol 2007;156:1235-44
78. Bathe A, Matterne U, Dewald M, et al. Educational multidisciplinary training programme for patients with chronic pruritus. Acta Derm Venereol 2009;89:498-01
79. Phan NQ, Blome C, Fritz F, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale (VAS), numerical rating scale (NRS) and verbal rating scale (VRS) in 471 chronic pruritus patients. Acta Derm Venereol 2011; In press
80. Ständer S, Blome C, Breil B, et al. Assessment of pruritus-current standards and implications for clinical practice : consensus paper of the Action Group Pruritus Parameter of the International Working Group on Pruritus Research (AGP). Hautarzt 2012;63:521-31
81. Reich A, Heisig M, Phan NQ, et al. Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Derm Venereol 2011;doi: 10.2340/00015555-1265
82. Blome C, Augustin M, Siepmann D, et al. Measuring patient-relevant benefits in pruritus treatment: development and validation of a specific outcomes tool. Br J Dermatol 2009;161:1143-8
83. Duval A, Dubertret L. Aprepitant as an antipruritic agent?. N Engl J Med 2009;361:1415-16
84. Vincenzi B, Fratto ME, Santini D, et al. Aprepitant against pruritus in patients with solid tumours. Support Care Cancer 2010;18:1229-30
85. Vincenzi B, Tonini G, Santini D. Aprepitant for erlotinib-induced pruritus. N Engl J Med 2010;363:397-8
86. Ständer S, Siepmann D, Herrgott I, et al. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One 2010;5:e10968
87. Walter M, Kottke T, Stark H. The histamine H4 receptor: targeting inflammatory disorders. Eur J Pharmacol 2011;668:1-5
88. Shin N, Covington M, Bian D, et al. INCB38579, a novel and potent histamine H4 receptor small molecule antagonist with anti-inflammatory pain and anti-pruritic functions. Eur J Pharmacol 2012;675:47-56
89. Suwa E, Yamaura K, Oda M, et al. Histamine H4 receptor antagonist reduces dermal inflammation and pruritus in a hapten-induced experimental model. Eur J Pharmacol 2011;667:383-8
90. Rossbach K, Wendorff S, Sander K, et al. Histamine H4 receptor antagonism reduces hapten-induced scratching behaviour but not inflammation. Exp Dermatol 2009;18:57-63